Clinical Trials Detail

SystHERs - An observational cohort study of treatment patterns and outcomes in patients with HER2 positive (HER2+) metastatic breast cancer



HER2 positive metastatic breast cancer.


This is an observational study designed to follow patients with HER2+ metastatic breast cancer and collect treatment information. Enrolled participants will receive treatment and evaluations for their HER2+ breast cancer as determined by their treating physicians, usually according to the standard of care and clinical practice at each study site. Information about baseline characteristics, disease history and prior treatment will be collected. Information on all changes in treatment and disease status will be collected every 90 days. Throughout the study, patients will answer questions about their treatment and quality of life.


  • To describe trends in treatment patterns a well as sequencing of treatments and clinical outcomes such as progression free survival and overall survival.
  • To study the effectiveness and safety of different HER2 targeted treatments and combinations of treatments.

Participating Physician Clinics

  • Family Cancer Center Foundation – Walnut Grove, Bartlett, Southaven, Oxford
  • Boston Baskin Cancer Foundation – East Memphis, Bartlett, Southaven

Clinical Trial Categories

  • Breast Cancer
Genentech, Inc.
How to Participate

Partial Inclusion Criteria

  • Diagnosis of HER2+ metastatic breast cancer, no more than 6 months prior to study enrollment.

For the current eligibility status of this clinical study, referring physicians may call the Baptist referral line at 901-227-DOCS (3627).